GlassScriptPhysician profile
William T Strahan
NPI 1619379831
$2,972.99
in general payments reported to CMS, 2019-2025
23 companies · $650 in 2025
The $650 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $274 · 2023: $1,148 · 2024: $901 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,698.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $798.92 | 2022-2025 | |
| Novo Nordisk INC | $518.86 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $376.18 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $214.45 | 2022-2025 | Farxiga, Airsupra |
| Corium, LLC | $205.99 | 2023-2025 | Azstarys |
| Abbott Laboratories | $109.38 | 2023-2025 | Freestyle Libre 3 |
| Tris Pharma INC | $80.00 | 2023-2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $76.18 | 2023-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.32 | 2023 | Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $64.32 | 2022-2024 | Trintellix |
| Axsome Therapeutics, INC. | $54.22 | 2025 | Auvelity |
| Tolmar, INC. | $53.12 | 2023-2025 | Jatenzo |
| Lundbeck LLC | $50.87 | 2022-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $47.87 | 2023-2024 | Rexulti |
| Pfizer INC. | $47.22 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $38.45 | 2025 | Fanapt |
| Exact Sciences Corporation | $36.65 | 2024-2025 | Cologuard Collection Kit |
| Bausch Health US, LLC | $32.72 | 2023 | Wellbutrin, Aplenzin |
| Shield Therapeutics INC | $32.52 | 2023 | Accrufer |
| Ironwood Pharmaceuticals, INC | $18.54 | 2024 | |
| Amgen INC. | $17.69 | 2024 | Repatha |
| Currax Pharmaceuticals LLC | $14.34 | 2023 | Contrave, Onzetra Xsail |
| Antares Pharma, INC. | $14.18 | 2024 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Strahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.